Caladrius and Cend Merge to Become Lisata Therapeutics
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 4 (Table of Contents)
Published: 30 Apr-2022
DOI: 10.3833/pdr.v2022.i4.2687 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Caladrius Biosciences and Cend Therapeutics have entered into a definitive merger agreement to form a combined company to be renamed Lisata Therapeutics...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS